RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GlaxoSmithKline Pharmaceuticals Stock

GlaxoSmithKline Pharmaceuticals Liabilities 2025

GlaxoSmithKline Pharmaceuticals Liabilities

17.79 B INR

Ticker

GLAXO.NS

ISIN

INE159A01016

In 2025, GlaxoSmithKline Pharmaceuticals's total liabilities amounted to 17.79 B INR, a 12.22% difference from the 15.85 B INR total liabilities in the previous year.

GlaxoSmithKline Pharmaceuticals Aktienanalyse

What does GlaxoSmithKline Pharmaceuticals do?

GlaxoSmithKline (GSK) is a global pharmaceutical company focused on the development, manufacturing, and marketing of prescription medicines, vaccines, and consumer products. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, the company has become one of the leading players in the pharmaceutical and healthcare industry. GSK's history began in 1859 with the opening of a pharmacy in New Zealand by Joseph Edward Nathan. In 1904, physician and researcher Joseph Nathan Cohen founded Glaxo Laboratories, which specialized in the production of vitamin preparations. Over the years, the company expanded and eventually merged with Wellcome plc in 1995 to form Glaxo Wellcome. SmithKline Beecham was founded in 1830 and expanded through acquisitions and mergers in the following decades. In June 2000, Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline. GSK's business model is based on research, development, and marketing of products aimed at improving patients' lives. The company has a wide range of products, including prescription medicines, vaccines, and consumer products. GSK operates in over 100 countries and employs over 100,000 people worldwide. GSK has various divisions, including pharmaceuticals, vaccines, and consumer healthcare. The pharmaceutical division is the company's core business and focuses on researching and developing innovative therapies in the areas of oncology, immunology, infectious diseases, and respiratory diseases. The company's vaccine division is involved in vaccine production and the development of new vaccine technologies. GSK is one of the largest vaccine manufacturers globally and produces vaccines against infectious diseases such as hepatitis A and B, meningococcal disease, pneumococcal disease, and HPV. The company's consumer healthcare division produces a wide range of products in the health and wellness sector, including dietary supplements, pain relievers, and skincare products under brands like Sensodyne, Voltaren, and Aquafresh. Some of GSK's most well-known products include the antidepressant Paxil, the asthma inhaler Advair, and the antimalarial medication Malarone. Additionally, GSK has played a leading role in addressing global health issues, such as developing a vaccine against Ebola and providing antiretroviral drugs for the treatment of HIV/AIDS. Overall, GlaxoSmithKline has established a strong position as one of the leading global pharmaceutical companies in recent years. The company pursues an innovative research and development strategy to promote forward-looking technologies that have the potential to change the way we perceive and treat diseases. With a strong focus on innovation, growth, and improving the quality of life for patients worldwide, GSK is on track to remain a significant player in the global healthcare industry. GlaxoSmithKline Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing GlaxoSmithKline Pharmaceuticals's Liabilities

GlaxoSmithKline Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating GlaxoSmithKline Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing GlaxoSmithKline Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

GlaxoSmithKline Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in GlaxoSmithKline Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals stock

What is the level of liabilities of GlaxoSmithKline Pharmaceuticals this year?

GlaxoSmithKline Pharmaceuticals has a debt balance of 17.79 B INR this year.

What were the liabilities of GlaxoSmithKline Pharmaceuticals compared to the previous year?

The liabilities of GlaxoSmithKline Pharmaceuticals have increased by 12.22% increased compared to the previous year.

What are the consequences of high debt for investors of GlaxoSmithKline Pharmaceuticals?

High liabilities can pose a risk for investors of GlaxoSmithKline Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in GlaxoSmithKline Pharmaceuticals?

Low liabilities mean that GlaxoSmithKline Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of GlaxoSmithKline Pharmaceuticals affect the company?

An increase in liabilities of GlaxoSmithKline Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of GlaxoSmithKline Pharmaceuticals affect the company?

A decrease in the liabilities of GlaxoSmithKline Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of GlaxoSmithKline Pharmaceuticals?

Some factors that can influence the liabilities of GlaxoSmithKline Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of GlaxoSmithKline Pharmaceuticals so important for investors?

The liabilities of GlaxoSmithKline Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can GlaxoSmithKline Pharmaceuticals take to modify the liabilities?

To change its liabilities, GlaxoSmithKline Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does GlaxoSmithKline Pharmaceuticals pay?

Over the past 12 months, GlaxoSmithKline Pharmaceuticals paid a dividend of 44 INR . This corresponds to a dividend yield of about 2.25 %. For the coming 12 months, GlaxoSmithKline Pharmaceuticals is expected to pay a dividend of 30.56 INR.

What is the dividend yield of GlaxoSmithKline Pharmaceuticals?

The current dividend yield of GlaxoSmithKline Pharmaceuticals is 2.25 %.

When does GlaxoSmithKline Pharmaceuticals pay dividends?

GlaxoSmithKline Pharmaceuticals pays a quarterly dividend. This is distributed in the months of August, July, June, December.

How secure is the dividend of GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals paid dividends every year for the past 23 years.

What is the dividend of GlaxoSmithKline Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 30.56 INR are expected. This corresponds to a dividend yield of 1.56 %.

In which sector is GlaxoSmithKline Pharmaceuticals located?

GlaxoSmithKline Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline Pharmaceuticals from 11/28/2024 amounting to 12 INR, you needed to have the stock in your portfolio before the ex-date on 11/7/2024.

When did GlaxoSmithKline Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/28/2024.

What was the dividend of GlaxoSmithKline Pharmaceuticals in the year 2024?

In the year 2024, GlaxoSmithKline Pharmaceuticals distributed 32 INR as dividends.

In which currency does GlaxoSmithKline Pharmaceuticals pay out the dividend?

The dividends of GlaxoSmithKline Pharmaceuticals are distributed in INR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GlaxoSmithKline Pharmaceuticals

Our stock analysis for GlaxoSmithKline Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.